AVRO AVROBIO Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AVRO

Price (delayed)

$1.22

Market cap

$54.73M

P/E Ratio

4.52

Dividend/share

N/A

EPS

$0.27

Enterprise value

-$42.7M

AVROBIO's vision is to bring personalized gene therapy to the world. The company aims to prevent, halt or reverse disease throughout the body with a single dose of gene therapy ...

Highlights
AVROBIO's quick ratio has soared by 119% YoY and by 10% from the previous quarter
AVRO's net income has surged by 111% year-on-year
AVROBIO's equity has increased by 26% YoY but it has decreased by 8% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.avrobio.com
Peers: OCX OGEN OLMA OMER

Key stats

What are the main financial stats of AVRO
Market
Shares outstanding
44.86M
Market cap
$54.73M
Enterprise value
-$42.7M
Valuations
Price to earnings (P/E)
4.52
Price to book (P/B)
0.57
Price to sales (P/S)
N/A
EV/EBIT
-4.22
EV/EBITDA
-3.38
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
$10.11M
EBITDA
$12.64M
Free cash flow
-$61.85M
Per share
EPS
$0.27
Free cash flow per share
-$1.4
Book value per share
$2.13
Revenue per share
$0
TBVPS
$2.28
Balance sheet
Total assets
$101.09M
Total liabilities
$6.35M
Debt
$878,000
Equity
$94.74M
Working capital
$93.91M
Liquidity
Debt to equity
0.01
Current ratio
15.78
Quick ratio
15.47
Net debt/EBITDA
-7.71
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
11.3%
Return on equity
13%
Return on invested capital
396.5%
Return on capital employed
10.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AVRO stock price

How has the AVROBIO stock price performed over time
Intraday
-3.17%
1 week
-2.4%
1 month
-6.15%
1 year
31.39%
YTD
-10.29%
QTD
-4.69%

Financial performance

How have AVROBIO's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
$10.19M
Net income
$12.16M
Gross margin
N/A
Net margin
N/A
AVRO's net income has surged by 111% year-on-year
AVRO's operating income has surged by 110% year-on-year

Growth

What is AVROBIO's growth rate over time

Valuation

What is AVROBIO stock price valuation
P/E
4.52
P/B
0.57
P/S
N/A
EV/EBIT
-4.22
EV/EBITDA
-3.38
EV/Sales
N/A
The EPS has surged by 111% year-on-year
AVRO's price to book (P/B) is 62% less than its 5-year quarterly average of 1.5 and 5% less than its last 4 quarters average of 0.6
AVROBIO's equity has increased by 26% YoY but it has decreased by 8% from the previous quarter

Efficiency

How efficient is AVROBIO business performance
The ROIC has soared by 150% YoY
The return on assets has surged by 115% year-on-year
AVROBIO's ROE has soared by 113% YoY

Dividends

What is AVRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AVRO.

Financial health

How did AVROBIO financials performed over time
AVROBIO's quick ratio has soared by 119% YoY and by 10% from the previous quarter
AVRO's current ratio has soared by 107% YoY and by 9% QoQ
AVRO's debt is 99% smaller than its equity
AVRO's debt has dropped by 95% year-on-year and by 50% since the previous quarter
The debt to equity has shrunk by 95% YoY and by 50% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.